Scanfil’s Sieradz factory to go into 100% fossil-free electricity
Scanfil plc Press release 14 December 2021 at 12.00 p.m. EEST
Scanfil’sSieradz factory to go into 100% fossil-free electricity
Scanfil’s Sieradz factory in Poland signed an agreement about switching to 100% fossil-free electricity. As of 1 January, 2022 Sieradz factory will be CO2 neutral in its electricity.
Sieradz factory is one of Scanfil’s biggest factories and has an annual electrical energy consumption of about 3,700 MWh. If this amount of energy would be produced with coal, it would create nearly 3,850 tons of CO2 emissions.
“By changing the energy source of our electricity, we can make a significant environmental impact,” states Scanfil’s Mats Lindblad, Director Quality Systems.” I am happy to see that we are moving fast and reducing our environmental impact.”
Scanfil and all of its factories are committed to improving its operations also from the environmental point of view. Sieradz is now the fourth factory within the Scanfil factory network that will be using only fossil-free electricity.
“The eagerness to do environmental actions are high in our production sites. All our factories are contributing to the Scanfil’s common goal, and we will reach our goals earlier than planned,” Mats Lindblad continues.
Scanfil has set science-based targets for significant reductions in greenhouse gas (GHG) emissions and is committed to reducing its carbon footprint by 35% from 2020 baseline to 2030, assuming that its organic growth remains at the current level. The company also commits that its energy consumption will be at least 50% fossil-free by 2030.
With the current pace, Scanfil will reach its target already before 2030.
Read more about Scanfil’s sustainability work: www.scanfil.com/sustainability
Mats Lindblad, Director of Global Quality Systems
Scanfil in brief
Scanfil is an international manufacturing partner and system supplier for the electronics industry with 40 years of experience in demanding manufacturing. Scanfil provides its customers with an extensive array of services, ranging from product design to product manufacturing, material procurement and logistics solutions. Vertically integrated production and a comprehensive supply chain are the foundation of Scanfil’s competitive advantages: speed, flexibility and reliability.
Typical Scanfil products are modules or integrated products for e.g. self-service application, automation systems, wireless connectivity modules, climate control systems, collection and sorting systems, analysers and environmental measurement solutions. Scanfil services are used by numerous international automation, safety, energy, cleantech, connectivity and health service providers, as well as companies operating in the field of urbanization. Scanfil’s network of factories consists of 9 production units in Europe, Asia and North America. Read more: www.scanfil.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada26.1.2022 07:00:00 CET | Press release
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomniaCollaboration with Syneos Health to effectively reach the primary care market in Europe and Canada Allschwil, Switzerland& Morrisville, N.C. – January26, 2022 Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada. Simon Jose, Chief Commercial Officer of Idorsia, commented: “Daridorexant represents a significant advance in the treatment of insomnia, and it is now our
Sharing of Staking Rewards Announcement26.1.2022 07:00:00 CET | Press release
January 26th 2022 CoinShares Digital Securities Limited CoinShares Physical Staked Tezos CoinShares Physical Staked Polkadot Sharing of Staking Rewards CoinShares Digital Securities Limited (the “Issuer”) hereby announces in accordance with Condition 5.3.2 of the Conditions of the CoinShares Digital Securities that Staking Rewards in relation to the class (the “Specified Class”) specified below will be applied by a reduction in the Management Fee applicable to the Specified Class to zero and a positive daily accrual to the Coin Entitlement to the Specified Class provided in the table below . Such reduction to the Management Fee and positive daily accrual to the Coin Entitlement shall apply from the start of trading on January 26th, 2022 until a date to be specified in a further announcement in accordance with Condition 5.3.2. ClassISINManagement FeeStaking Reward (positive daily accrual to Coin Entitlement) CoinShares Physical Staked Tezos GB00BMWB4803 Reduced to 0.0% p.a. 3.00% p.a. C
Aino Health AB (publ): Norberg & Partner Sustainable Group AB (publ) tecknar aktier i Aino Health AB (publ).25.1.2022 19:45:00 CET | Pressemelding
Detta pressmeddelande utgör inte ett offentligt uppköpserbjudande eller annars ett erbjudande om att förvärva aktier. Norberg & Partner Sustainable Group AB (publ)tecknar aktier i Aino Health AB (publ) och utlöser därmed budplikt. Norberg & Partner Sustainable Group AB (publ), org.nr 559268-0663 (”Norberg & Partner”) har idag tecknat 15 384 616 aktier i Aino Health AB (publ), org.nr 559063-5073 (”Aino Health”) till ett pris om 0,65 kronor per aktie. Efter förvärvet äger Norberg & Partner cirka 36,38 procent av aktierna och rösterna i Aino Health. Genom förvärvet utlöses budplikt, vilket innebär att Norberg & Partner är skyldig att offentliggöra ett budpliktsbud avseende resterande aktier i Aino Health inom fyra veckor från förvärvet, alternativt avyttra så många aktier så att aktieinnehavet representerar mindre än tre tiondelar av röstetalet för samtliga aktier i Aino Health. För ytterligare information, se Norberg & Partners hemsida. www.norbergpartner.se/ Kontaktperson: Jyrki Eklund,
Sword Group: 2021 Fourth Quarterly Results | Exceptional Profitability25.1.2022 19:15:00 CET | Press release
2021 Fourth Quarterly Results Consolidated Revenue: €59.7m Consolidated Growth: +31.8% Organic Growth: +21.9% EBITDA Margin: 15.0% RESULTS 4TH QUARTER 2021 Q4 (1) €m 2021 2020 Revenue 59.7 45.3 EBITDA 9.0 7.6 EBITDA Margin 15.0% 13.0% (1) non audited figures Organic growth on a like-for-like basis and at constant exchange rates: +21.9%. YEAR 2021 Consolidated Revenue: €214.6m Organic Growth: +21.5% EBITDA Margin: 13.6% ANALYSIS The Revenue for the Fourth Quarter of 2021 amounts to €59.7m in consolidated terms and to €55.2m without taking into account the acquisition of AiM, added to the perimeter on 1 July 2021. The EBITDA margin for the quarter amounts to 15.0% and organic growth to +21.9%. For 2021, the consolidated revenue amounts to €214.6m with an EBITDA margin of 13.6%. Organic growth for the year amounts to +21.5%. The Group established its 2021 Business Plan based on an organic growth hypothesis of 13%. Sword outperformed in terms of growth while maintaining and even exceeding
Aino Health AB (publ): The board of Aino Health resolves on a directed issue of shares to Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Press release
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. The board of Aino Health AB (publ), reg. number 559063-5073 (the “Company”) has today, based on the authorisationfrom the annual general meeting on 24th of May 2021, resolved on a directed issue of 15 384 616 shares with deviation from the shareholders’ pre-emption right.The issue is directed to Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) in order to secure the Company’s long-term financing in a time-and cost-efficient manner and entails an estimated capital injection of approximately SEK 10 million. The subscription price was, after negotiations with the subscriber, determined to SEK 0.65 per new share, which corresponds to the market value as assessed by the board. The reason for the deviation from the shareholders’ pre-emptive right is to secure the Company’s long-term financing in a time- and cost-efficient manner. The new shar
Aino Health AB (publ): Styrelsen i Aino Health AB (publ) beslutar om en riktad nyemission till Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Pressemelding
Styrelsen i Aino Health AB (publ), org.nr 559063-5073 (”Bolaget”) har, med stöd av bemyndigandet från årsstämman den 24 maj 2021, idag beslutat att genomföra en riktad nyemission av 15 384616 aktier med avvikelse från aktieägarnas företrädesrätt. Nyemissionen är riktad till Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) i syfte att säkra Bolagets långsiktiga finansiering och medför ett förväntat kapitaltillskott om ca 10 miljoner kronor. Teckningskursen har efter förhandling med teckningsberättigade fastställts till 0,65 kronor per aktie, vilket motsvarar av styrelsen bedömt marknadsvärde. Skälet till avvikelsen från aktieägarnas företrädesrätt är att emissionslikviden ska användas i syfte att på ett snabbt och kostnadseffektivt sätt stärka Bolagets långsiktiga finansiering. Betalning för de nyemitterade aktierna sker genom kontant betalning. Antalet aktier i Bolaget ökar med 15 384 616 aktier, från 26 901 155 aktier till 42 285 771 aktier. Aktiekapitalet i Bolaget
EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS25.1.2022 18:00:00 CET | Press release
EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS At an Extraordinary General Meeting, Sika’s shareholders approved the increase of conditional capital. Sika recommends the election of Gordana Landento the Board of Directors at the next Annual General Meeting, to be held on April 12, 2022. On January 25, 2022, an Extraordinary General Meeting of Sika AG was held. Based on Ordinance 3 of the Federal Council on measures to prevent the spread of COVID-19, it was not possible for shareholders to physically attend the Extraordinary General Meeting. Instead, shareholders cast their votes through the independent proxy. The shareholders approved an increase to the existing conditional capital from CHF 155,893.20 (corresponding to 15,589,320 registered shares with a par value of CHF 0.01 each) to CHF 187,893.20 (corresponding to 18,789,320 registered shares with a par value of CHF 0.01 each). Shareholder